Multiple Myeloma Articles

Frontline Approaches Focus on Depth of Response in Newly Diagnosed Myeloma
Giada Bianchi, MD, discusses the scope of frontline therapy and subsequent maintenance strategies among patients with transplant eligible and ineligible newly diagnosed multiple myeloma.
Carfilzomib Continues to Show Frontline Potential in Myeloma
Juan P. Alderuccio, MD, discusses the current state of the treatment paradigm in multiple myeloma and ongoing challenges that remain. 
Salvage Daratumumab Reaches High ORR in Relapsed Myeloma Following Allogeneic SCT
Patients with multiple myeloma who relapsed following allogeneic stem cell transplantation and also failed several posttransplant therapies demonstrated a strong response to daratumumab salvage therapy.
EU Panel Backs Lenalidomide- and Pomalidomide-Based Triplets for Myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted positive opinions to 2 triplet regimens with immunomodulatory agents for patients with multiple myeloma.
EU Application Filed for Daratumumab in Newly Diagnosed, Transplant-Eligible Myeloma
A Type II variation application has been submitted to the European Medicines Agency for the 4-drug regimen of daratumumab, bortezomib, thalidomide, and dexamethasone as a treatment for patients with newly diagnosed multiple myeloma who are eligible to undergo autologous stem cell transplant.
FDA Approval Sought for Frontline Daratumumab Regimen in Transplant-Eligible Myeloma
A supplemental biologics license application has been submitted to the FDA for daratumumab in combination with bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Emerging Treatments in Multiple Myeloma Spark Prospect for Cure
James E. Hoffman, MD, discusses the current treatment options available for patients with multiple myeloma, underscores remaining challenges in the space, and shares predictions for where the field is headed.
 
EU Approval Sought for Frontline Daratumumab/Rd in Transplant-Ineligible Myeloma
A Type II variation application has been submitted to the European Medicines Agency for the combination of daratumumab with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.
BCMA Antibody-Drug Conjugate Continues to Extend PFS in Relapsed/Refractory Myeloma
The investigational antibody-drug conjugate GSK2857916 continued to improve progression-free survival in patients with relapsed/refractory multiple myeloma, according to results of a final analysis of the DREAMM-1 study.
FDA Halts Enrollment on Venetoclax Myeloma Trials
The FDA has placed a partial clinical hold on all clinical trials examining venetoclax in multiple myeloma, halting enrollment of new patients on the studies.
Publication Bottom Border
Border Publication
x